Live·Verified funding discovery · 2026.2
874 grants · 19 open · 435 companies · 2640 concepts874 / 19 / 435 / 2640
△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA△COMPANIESCompanies rated · 435 (no change)△PROJECTSProjects rated · 70 (no change)△CATALOGUE874 grants in catalogue · 19 open right now•POWERED BYOpen Longevity · 501(c)(3) · Sherman Oaks, CA
Ratings

Eternal Search

Heroes

People whose work, funding, scientific leadership, and multiplier effects have shaped the longevity field.

Every score here rates one thing: longevity commitment. The role tags — scientist, investor, founder, and the rest — describe what a person does. We do not compute a separate rating for each tag.

Scoring AI engine · v0.9.0

RolesAllcliniciancommunicatorentrepreneurinvestoroperatorphilanthropistpopulariserscientistself-experimenter
ThemesAllDestinationMeta ViewPathRisk ViewTimeline
SortOverallRecently updatedFuture visionScientific impactCapital deployedStrategic tasteField creationBravery and convictionMultiplier effect
#ScoreHeroDimensionsScored
163
George Churchv0.4.0
Church helped make longevity a genomics problem: aging-expression signatures, naked mole-rat transcriptomics, and screen pipelines. Not immortality dust; useful machinery.
scientistentrepreneurinvestor
7/7254
Laura Demingv0.4.0
Deming helped drag longevity biotech from weird sidebar into fundable company-building, then put her current bet on reversible organ cryopreservation. Not proof of victory; proof of taste.
investorentrepreneurpopulariser
7/7350
Eric Verdinv0.4.0
Verdin helped drag geroscience from aging folklore into citation-heavy biology: 73,392 citations, h-index 133, and major work on NAD+, sirtuins, inflammation, and aging biomarkers.
scientistentrepreneurinvestor
7/7449
Michael Grevev0.6.0
Greve helped make longevity more operational: Forever Healthy pushes intervention reviews and translation of molecular repair research into therapies. The capital claims are thinner than the legend.
investorphilanthropistentrepreneur
7/7544
Jim Mellonv0.4.0
Mellon helped make longevity biotech legible as a company category, mainly through Juvenescence and field-definition papers. Scientific footprint: modest, not mythical.
entrepreneurinvestorphilanthropist
7/7641
Anar Ismanv0.4.0
Isman’s impact is practical, not mythic: AgelessRx-linked studies put off-label rapamycin, LDN/NAD+, and QoL endpoints into real-world longevity data. Useful work; not field conquest.
entrepreneurscientistinvestor
7/7740
Kai Micah Millsv0.4.0
Mills has pushed longevity toward cryonics infrastructure, not wellness theater, by building Cryopets and CryoDAO and publicly framing death as a technical problem. Evidence is thin; this is movement-building, not proven impact yet.
entrepreneurpopulariserinvestor
7/7840
Nathan Chengv0.4.0
Cheng helped give longevity’s speculative edge an address: co-founding Longevity Biotech Fellowship and co-authoring a 2024 biostasis roadmap. The science is early; the agenda is concrete.
populariserentrepreneurinvestor
7/7934
Sergey Youngv0.4.0
Sergey Young helped put investor attention into longevity through Longevity Vision Fund and field-definition work. The record shows visibility, not proof of big deployed capital.
investorpopulariserphilanthropist
7/71031
Adam Griesv0.4.0
Gries has helped make longevity look like a founder market, not just a lab topic. The hard proof is still thin: mostly Vitalist Bay convening claims and public vitalist signal, not documented capital or science.
populariserinvestor
7/71130
Peter Diamandisv0.4.0
Diamandis helped push longevity toward AI-led health tracking and company-building, not lab-defining science. The evidence shows one aging-clock paper with 29 citations and thin disclosed capital.
entrepreneurpopulariserinvestor
7/71230
Yuri Milnerv0.4.0
Milner is weakly linked to Altos Labs, making his visible longevity impact a reported bet on cellular reprogramming rather than a proven field record. Thin evidence, so no victory lap.
philanthropistinvestorentrepreneur
6/71327
Karl Pflegerv0.4.0
Pfleger helped make aging biotech more legible through AgingBiotech.info and coauthored a paper arguing that healthy life extension has far more public demand than sloppy surveys suggested.
populariserinvestorphilanthropist
6/71424
Omri Droryv0.4.0
Drory helped frame longevity as techbio infrastructure work, not wellness theater: measure biology better, then pursue reprogramming, regeneration, and replacement. Evidence is thin; call this a signal, not proven field impact.
investorentrepreneurself-experimenter
7/71523
Jeff Bezosv0.4.0
No usable evidence here shows Bezos changed longevity beyond a reported Altos Labs link. For a billionaire, that is a very thin public footprint, not a legacy.
investor
7/7169
Sam Altmanv0.4.0
No public longevity impact is supported here. The only cited paper is by Soya S Sam on an HIV assay, not Sam Altman, so crediting Altman would be spreadsheet cosplay.
investorself-experimenter
7/7